Evra

norelgestromin / ethinyl estradiol

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Evra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evra.

For practical information about using Evra, patients should read the package leaflet or contact their doctor or pharmacist.

What is Evra and what is it used for?

Evra is a contraceptive used to prevent pregnancy. Its safety and effectiveness have been studied in women aged 18 to 45 years.

It contains two active substances: norelgestromin (6 mg) and ethinylestradiol (600 micrograms).

How is Evra used?

Evra is a transdermal patch (a patch that delivers a medicine across the skin). For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free. The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms. Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back. The same area of skin should not be used for two consecutive patches. Evra may work less well in women weighing 90 kg or more.

For full instructions on how to use Evra, see the package leaflet.

The medicine can only be obtained with a prescription.

How does Evra work?

Evra is a transdermal patch version of ‘the pill’ (combined oral contraceptive tablet). Using a weekly transdermal patch instead of a daily pill may help the woman to stick to using her contraception appropriately. The active substances in Evra are two hormones, ethinylestradiol (an oestrogen) and norelgestromin (a progestogen). Ethinylestradiol has been in use extensively in oral contraceptives for many years, and norelgestromin is very similar to another progestogen, which is also used in some oral contraceptives. Evra works like the pill by changing the body’s hormonal balance to prevent ovulation, by altering the cervical mucus and by thinning the endometrium (the lining of the womb).

What benefit of Evra has been shown in studies?

Evra has been shown to be an effective contraceptive. It was studied in three main studies in over 3,000 women, which determined the number of women who became pregnant while taking the medicine. In two studies, Evra was compared with combined oral contraceptives: in one study, the comparator was a ‘monophasic’ contraceptive (pill containing the same amounts of active substances over the first three weeks of the treatment cycle) and in the other study, they were ‘triphasic’ (with the amount of the active substances in the pills varying through the treatment cycle). The third study did not compare Evra with any other medicine. All of the studies lasted for a year (13 four-week cycles).

Overall in the three studies, 15 pregnancies occurred in women taking Evra, 12 of which were the result of a ‘method failure’ (when a pregnancy occurs despite the contraceptive being used correctly). Five of the pregnancies were in women weighing over 90 kg. This gives Evra a ‘Pearl Index’ of 0.90. The Pearl Index is a standard way of measuring the effectiveness of contraceptives, which measures how many unwanted pregnancies occur in 100 woman-years (corresponding to 1,300 cycles), with lower values indicating more effective contraception. The Pearl Indices for the oral contraceptives were 0.57 (monophasic) and 1.28 (triphasic).

What are the risks associated with Evra?

The most common side effects with Evra (seen in more than 1 patient in 10) were headache, nausea (feeling sick) and breast tenderness.

Evra must not be used when a woman has, or has had blood clots in the veins or arteries including a stroke or a heart attack or when a woman has risk factors for blood clots (such as severe high blood pressure, diabetes with damage to the blood vessels, high cholesterol levels, or a family history of thrombosis). It must not be used in women who have migraine with aura (unusual visual or other sensory experiences), severe liver problems, liver tumours or a history of liver tumours, some types of cancer or abnormal bleeding from the genital area whose cause has not been diagnosed. It must also not be used together with certain antiviral medicines containing the active substances ombitasvir, paritaprevir, ritonavir and dasabuvir. For the full list of all side effects and restrictions, see the package leaflet.

Why is Evra approved?

The European Medicines Agency decided that Evra’s benefits are greater than its risks for female contraception and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe and effective use of Evra?

The company that markets Evra will perform a study to further investigate the risk of blood clots.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Evra have also been included in the summary of product characteristics and the package leaflet.

Other information about Evra

The European Commission granted a marketing authorisation valid throughout the European Union for Evra on 22 August 2002.

For more information about treatment with Evra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Evra : EPAR - Summary for the public BG = bălgarski 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public ES = español 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public CS = čeština 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public DA = dansk 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public DE = Deutsch 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public ET = eesti keel 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public EL = elliniká 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public EN = English 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public FR = français 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public IT = italiano 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public LV = latviešu valoda 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public LT = lietuvių kalba 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public HU = magyar 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public MT = Malti 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public NL = Nederlands 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public PL = polski 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public PT = português 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public RO = română 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public SK = slovenčina 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public SL = slovenščina 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public FI = suomi 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public SV = svenska 2008-08-05 2017-07-25
Evra : EPAR - Summary for the public HR = Hrvatski 2008-08-05 2017-07-25

This EPAR was last updated on 25/07/2017 .

Authorisation details

Product details

Product details for Evra
NameEvra
Agency product numberEMEA/H/C/000410
Active substance

norelgestromin / ethinyl estradiol

International non-proprietary name (INN) or common name

norelgestromin / ethinyl estradiol

Therapeutic area Contraception
Anatomical therapeutic chemical (ATC) code G03AA13

Publication details

Publication details for Evra
Marketing-authorisation holder

Janssen-Cilag International NV

Revision18
Date of issue of marketing authorisation valid throughout the European Union22/08/2002

Contact address:

Janssen-Cilag International NV
Turnhoutseweg, 30
B-2340 Beerse
Belgium

Product information

Product information

23/06/2017  Evra -EMEA/H/C/000410 -II/0041

Name Language First published Last updated
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25
Evra : EPAR - Product Information HR = Hrvatski 2009-04-06 2017-07-25

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06
Evra : EPAR - All Authorised presentations HR = Hrvatski 2005-10-21 2009-04-06

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Female contraception.

Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Evra : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2009-04-06 2017-07-25
Evra-H-C-410-A31-1356 : EPAR - Assessment Report - Article 31 HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisations, and detailed explanation for the differences from the PRAC recommendation. CHMP members’ divergent positions HR = Hrvatski 2014-04-08  
Evra : EPAR - Steps taken after authorisation when a cutoff date has been used HR = Hrvatski 2005-10-21  

Initial marketing-authorisation documents

Name Language First published Last updated
Evra : EPAR - Procedural steps taken before authorisation HR = Hrvatski 2005-10-21  
Evra : EPAR - Scientific Discussion HR = Hrvatski 2005-10-21  

Authorised

This medicine is approved for use in the European Union

More information on Evra